Diabetes technology & therapeutics · 2026
Comparison of Blood Glucose Values Used for Impending Non-Severe Hypoglycemia Management with Corresponding Continuous Glucose Monitoring Data in Type 1 Diabetes: A Secondary Analysis of the REVERSIBLE Trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marquis Andréanne, Cheng Ran, Al-Mahayni Sara, Osman Ahmed, Molveau Josephine, Messier Virginie, Rabasa-Lhoret Rémi, Taleb Nadine
Аннотация
BACKGROUND: To assess continuous glucose monitoring (CGM) data corresponding to blood glucose (BG) values used for impending non-severe (NS) hypoglycemia management in people living with type 1 diabetes (PwTID).
METHODS: We performed a secondary analysis of the REVERSIBLE trial, a three-arm open-label crossover study assessing the efficacy of 16 g oral carbohydrates (CHO) for preventing NS hypoglycemia at different BG levels: <72 mg/dL (4 mmol/L, level 1), ≤80 mg/dL (4.5 mmol/L), or ≤90mg/dL (5.0 mmol/L). CGM data (DexcomG6®) were compared with BG to assess their variances and mean absolute relative differences (MARDs).
RESULTS: In all three arms CGM values overestimated BG levels (P < 0.001). MARDs were higher with lower BG values. Despite these differences, we did not observe rebound hyperglycemia (BG > 180 mg/dL; 10 mmol/L).
CONCLUSION: When using CGM, PwTID may need to treat or prevent NS hypoglycemia at a higher threshold than 72 mg/dL (4.0 mmol/L) and 80 mg/dL (4.5 mmol/L), respectively.
METHODS: We performed a secondary analysis of the REVERSIBLE trial, a three-arm open-label crossover study assessing the efficacy of 16 g oral carbohydrates (CHO) for preventing NS hypoglycemia at different BG levels: <72 mg/dL (4 mmol/L, level 1), ≤80 mg/dL (4.5 mmol/L), or ≤90mg/dL (5.0 mmol/L). CGM data (DexcomG6®) were compared with BG to assess their variances and mean absolute relative differences (MARDs).
RESULTS: In all three arms CGM values overestimated BG levels (P < 0.001). MARDs were higher with lower BG values. Despite these differences, we did not observe rebound hyperglycemia (BG > 180 mg/dL; 10 mmol/L).
CONCLUSION: When using CGM, PwTID may need to treat or prevent NS hypoglycemia at a higher threshold than 72 mg/dL (4.0 mmol/L) and 80 mg/dL (4.5 mmol/L), respectively.